News

Public · Published

RBC Capital maintains Eli Lilly at Outperform, raises price target to $1600 from $1500

RBC Capital kept an Outperform rating on Eli Lilly and raised its price target to $1600 from $1500, a 6.7% increase. That target implies 16.5% upside from the October 29 close of $1373.70.

Published:

Updated:

What happened

RBC Capital kept an Outperform rating on Eli Lilly and raised its price target to $1600 from $1500, a 6.7% increase. That target implies 16.5% upside from the October 29 close of $1373.70.

Confirmed

Global impact / market context

A higher price target signals that this analyst expects more room for the share price to rise. Because the target implies 16.5% upside, it may support investor confidence in Eli Lilly shares and draw attention from people deciding where to put money.

Analyst inference

Other recent analyst notes on Eli Lilly show targets from $1316 to $1550, so the new $1600 target sits above that recent range. This points to a more positive view from RBC Capital than several other research firms over the past month.

Analyst inference

What to watch

  1. Watch whether other analysts change their Eli Lilly price targets following RBC Capital's move to $1600, compared with the recent $1316 to $1550 range. Confirmed
  2. Investors could compare the new $1600 target with the October 29 closing price of $1373.70 and decide whether the implied 16.5% upside fits their own expectations and risk tolerance. Proposed
  3. Track Eli Lilly's future results and company updates to see whether actual business performance supports the more positive view behind RBC Capital's higher price target. Analyst inference

Evidence

  • Original source link unavailable